7/7 2021

Ischemix, Inc. receives US Department of Defense funding of $2.9 million to conduct Phase 1 study of CMX-2043, a novel compound for the treatment of acute TBI

2021-07-07T20:27:53+00:00July 7th, 2021|ATI in the News|

This competitive award was granted by US Army Medical Research and Development Command (USAMRDC), Combat Casualty Care Research Program (CCCRP) in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium.

6/15 2021

$3.4 million grant to study the treatment of memory loss in patients with traumatic brain injury

2021-07-07T19:18:51+00:00June 15th, 2021|ATI in the News|

The project, sponsored by the U.S. Army Medical Research and Development Command (USAMRDC) and awarded through the Medical Technology Enterprise Consortium, will fund clinical studies of neurosurgical patients at Thomas Jefferson University Hospital, UT Southwestern Medical Center, the University of Texas at San Antonio, Emory University, and Dartmouth University.

6/2 2021

Centivax and U.S. Naval Medical Research Center announce strategic partnership to initiate clinical development of a broad-spectrum injectable for COVID-19, with $4.2M from the Henry Jackson Foundation

2021-07-07T19:43:02+00:00June 2nd, 2021|ATI in the News|

"With discovery research supported by Medical Technology Enterprise Consortium, and now clinical development supported by our remarkable collaboration with the Naval Medical Research Center, this biotech-government partnership is proud to advance this molecule into clinical development and closer to the patients and doctors that need a better medicine to end the pandemic."

5/26 2021

MTEC member researches treatment of septic shock, the cause of 70% of COVID deaths

2021-07-07T19:50:26+00:00May 26th, 2021|Success Stories|

Vivacelle Bio, Inc., a non-traditional small business and Medical Technology Enterprise Consortium (MTEC) member, was awarded $5.3 million to research treatment of septic shock.

Go to Top